1. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011. 29:744–751.
Article
2. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone. 1992. 13:Suppl 1. S7–S15.
Article
3. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int. 2005. 16:Suppl 2. S8–S17.
Article
4. Mullen JO, Mullen NL. Hip fracture mortality. A prospective, multifactorial study to predict and minimize death risk. Clin Orthop Relat Res. 1992. 280:214–222.
5. Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000. 11:460–466.
Article
9. Langdahl BL, Harsløf T. Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis. 2011. 3:17–29.
Article
10. Black DM, Thompson DE, Bauer DC, et al. FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000. 85:4118–4124.
Article
11. Pueyo MJ, Larrosa M, Suris X, et al. Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia. Reumatol Clin. 2012. 8:128–134.
Article
12. Muller D, Pulm J, Gandjour A. Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health. 2012. 15:284–298.
Article
13. Hiligsmann M, McGowan B, Bennett K, et al. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health. 2012. 15:604–612.
Article
14. Borgstrom F, Kanis JA. Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008. 22:885–900.
Article
15. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int. 2007. 18:9–23.
Article
16. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003. 21:305–314.
Article
17. Kim SR, Ha YC, Park YG, et al. Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study. J Korean Med Sci. 2011. 26:1501–1507.
Article
18. Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture. J Am Geriatr Soc. 2000. 48:1261–1263.
Article
19. ICANN Accredited Registrar. Uk-domains with anycastnamservers. 2011. cited by 2012 December 14. Available from:
www.nic.org.uk.
20. Australian Government Department of Health and Ageing. Pharmaceutical benefits scheme (PBS). 2012. cited by 2012 December 14. Available from:
www.pbs.gov.au.
21. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010. 16:1016–1019.
Article
22. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008. 149:404–415.
Article
23. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008. 19:399–428.
Article